Impaired Health‐Related Quality of Life in Patients With Hemophilia A With Inhibitors
Patients’ responses to surveys assessing quality of life indicated impairment in both adults and adolescents.
Bleeding Disorders
BLEEDING DISORDERS
LATEST ARTICLES
Diagnostic Utility of Bleeding Assessment Tool for Identifying Platelet Function Disorders
A bleeding assessment tool yielded higher scores for patients with suspected or confirmed platelet function disorders.
Detection and Management of Factor XIII A-Subunit Deficiency in Neonates
Researchers analyzed the clinical features of factor XIII deficiency in neonates and used the data to develop a diagnostic algorithm.
Bleeding Risks for Patients With Cancer on Anticoagulant Therapy
For all anticoagulants examined, patients with cancer had higher bleeding incidence rates than patients without cancer.
Treating Major Bleeding in Patients Taking Direct-Acting Oral Anticoagulants
There was no difference in mortality rate between patients taking various direct-acting oral anticoagulants (DOACs), though bleeding locations varied for each DOAC.
The Role of Cardiovascular Diseases in the Pathogenesis of Acquired von Willebrand Syndrome
High shear stress in blood vessels due to cardiovascular disease may be associated with the development of acquired von Willebrand syndrome.
Whole Blood Ristocetin-Induced Platelet Aggregometry for Determining von Willebrand Disease Severity
Assay values were not strongly correlated with von Willebrand factor ristocetin cofactor or antigen activity.
Addressing Shortcomings in Management of Heavy Menstrual Bleeding in Adolescents
Because most studies on heavy menstrual bleeding have been conducted in adults, treatment guidelines for adolescents are lacking.
Discriminating Coagulation Patterns in Cyanotic, Noncyanotic Congenital Heart Disease
Patients with cyanotic congenital heart diseases were found to have higher levels of hematocrit, hemoglobin, and reticulocytes.
Novel Reversal Agent for Ticagrelor Gets FDA’s Breakthrough Tx Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PB2452 (PhaseBio), an investigational reversal agent for ticagrelor.
Novel Mutations Associated With Hereditary Factor X Deficiency Identified
Researchers identified 11 novel mutations that may play a pathogenic role in hereditary factor X deficiency.
Intracranial Bleeding Rates in Neonates With Hemophilia by Mode of Delivery
Neonates with hemophilia who were delivered either vaginally or by Cesarean section had similar rates of intracranial bleeding.
Management of Intracranial Hemorrhage in Patients With Hemophilia
Researchers reviewed 33 studies published over a span of 20 years to identify risk factors and symptoms of intracranial hemorrhage in patients with hemophilia.
Once-Weekly Prophylaxis for Low-Bleeding Patients With Severe Hemophilia A
Once-weekly prophylactic injection of glycopegylated recombinant factor VIII (N8‐GP) for severe hemophilia A appears to be efficacious and safe, according to results from the pathfinder 2 extension phase. The study, published in Haemophilia, included patients aged 12 years or older with severe hemophilia A who had experienced up to 2 bleeds during the pathfinder 2…
Safety of Buccal Administration of Dental Anesthetic in Patients With Hemophilia
Current guidelines do not adequately inform management of patients with inherited bleeding disorders undergoing routine dental procedures.
New Tool for Reconstituting Factor VIII for Hemophilia A Prophylaxis
Simplifying factor VIII reconstitution may increase treatment adherence and satisfaction in patients with hemophilia A.
Optimal Platelet Transfusion Threshold Unknown in Patients Undergoing Lumbar or Epidural Procedures
Unnecessarily high platelet count thresholds may expose patients undergoing lumbar or epidural procedures to excessive transfusion-related risks.
Advances in the Treatment of Hemophilia: Clinical Gene Therapy
Gene therapy with adeno-associated viral viruses could provide an efficacious, safe, and cost-effective treatment option for patients with hemophilia.
Congenital Bleeding Disorders Not Associated With Increased Endoscopic Bleeding Risk With Proper Prophylaxis
Researchers conducted a retrospective chart review to assess the bleeding risk associated with gastrointestinal endoscopy.
Sex-Specific Models for Predicting Bleeding Risk Associated With Aspirin Use
Researchers assessed potential risk factors for major bleeding in patients without cardiovascular disease to develop sex-specific prediction models.
Efficacy of Secondary Prophylaxis in Patients With Severe Inherited von Willebrand Disease
Researchers assessed whether prophylactic treatment with von Willebrand factor/factor VIII concentrates reduced bleeding risk.
A Novel Screening Program for Severe Combined Immunodeficiency in Newborns
Population-based screening of newborns is crucial to identifying severe combined immunodeficiency before the onset of potentially fatal infection.
Esperoct Approval Provides New Treatment Option for Hemophilia A
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of patients with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes and perioperative management of bleeding.
Long-Term Outcome Profile in Patients With Acquired Hemophilia A
Underlying lymphoproliferative syndromes, male gender, and older age may be predictive of relapse in patients with acquired hemophilia A.
Episodic Treatment Compared With Prophylaxis in Patients With Hemophilia A
Researchers assessed safety outcomes in patients with hemophilia A without inhibitors.
Assessing Children With Bleeding Symptoms: Coagulation Disorder or Abuse?
Several factors need to be considered when determining whether a child’s bleeding symptoms are the result of a coagulation disorder, physical abuse, or both.
Pharmacokinetics-Based Hemophilia A Prophylaxis May Improve Clinical Outcomes
Researchers assessed the influence of adopting population pharmacokinetics to inform prophylaxis for patients with hemophilia A.
Andexanet Alfa Efficacious in Reducing Antifactor Xa Activity
Acute major bleeding decreased by 92% in patients who were treated with andexanet alfa.
Use of Rotational Thromboelastometry With Ristocetin to Identify Clinically Relevant von Willebrand Disease
Using rotational thromboelastometry may allow assessment of bleeding risks in patients with clinically relevant von Willebrand disease.
Safety Comparison of Apixaban vs Rivaroxaban for Thromboembolism Prevention
Researchers conducted the first real world study to compare the safety and effectiveness of apixaban and rivaroxaban in patients with VTE.
Updates to Transfusion Strategies for Major Hemorrhage in Trauma
Changes in clinical management of trauma hemorrhage have significantly reduced mortality rates, but variation in treatment strategies still remains.
Tranexamic Acid Concentrations Required for Fibrinolysis Inhibition
The need for tranexamic acid to be administered intravenously creates a barrier to rapid treatment of patients with fibrinolysis.
Improving the Clinical Diagnosis of Inherited Bleeding Disorders
Many unique challenges surround the diagnosis and treatment of inherited mild bleeding disorders.
Researchers Review Coagulation Risk Factors in Neonates and Children
The interactions between von Willebrand factors and its cleaving protease ADAMTS-13 recently emerged as risk factors for pediatric thromboembolism.
Self-Reported Bleeding Symptoms May Not Be Associated With Greater Fibrinolytic Activity
Propensity for bleeding was previously thought to relate to greater fibrinolytic activity, but this may not be the case.
Using Diluent Buffer May Lead to Overestimation of Low Factor VIII Levels
Accurate measurement of low factor VIII levels is necessary for proper monitoring of factor VIII replacement therapy.
Clot Waveform Analysis: A Novel Method to Classify Fibrinogen Disorders
Clot waveform analysis of the Clauss fibrinogen assay may allow classification of fibrinogen disorders without measuring fibrinogen antigen levels.
FDA Approval Expands Access to Factor Xa Inhibitor Antidote Andexxa
Andexxa was initially granted accelerated approval in May 2018 for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation was needed due to life-threatening or uncontrolled bleeding.
FDA Approves Updated Labeling for Hemophilia A Treatment Novoeight
The indication has been changed from “control and prevention of bleeding episodes” to “on-demand treatment and control of bleeding episodes” in adults and children with hemophilia A.
Amicar Tablet Generic Gets FDA Approval
Aminocaprioc Acid Tablets are useful in enhancing hemostasis when fibrolysis contributes to bleeding.
Advances in Treatment and Prevention of Hemophilia A: Takeaways From the 2018 ASH Annual Meeting
Research presented at the 2018 ASH Annual Meeting provided insights into the role of factor VIII as a therapeutic agent for severe hemophilia A.
Andexanet Alfa and the Role of Reversal Agents for Factor Xa Inhibitors
Andexanet alfa is the first anticoagulant reversal agent to receive global US FDA approval for patients with life-threatening or uncontrolled bleeding.
Should Infants Be Treated With von Willebrand Factor Concentrate After Complex Cardiac Surgery?
Researchers comment on the implications of treating newborns and infants with von Willebrand factor (VWF) concentrate.
Clinical Diagnosis of Factor V Inhibitors: A Single Institution’s Experience
A review of the management and outcomes for patients with autoimmune Factor V (FV) inhibitors.
Factor VIII, Factor IX Levels May Have Predictive Value in Identifying Severity of Hemophilia
Residual plasma levels of clotting factor XIII or factor IX accounted for around 70% of bleeding phenotype in patients with clinically severe hemophilia.
FDA Approves Expanded Indication for Hemlibra in Hemophilia A
The expanded approval was based on data from two Phase 3 clinical trials: HAVEN 3 and HAVEN 4.
Jivi With Step-Wise Dosing Approved for Management of Hemophilia A
The approval was supported by data from the phase 2/3 international, open-label PROTECT VIII trial (N=126) that evaluated previously treated patients aged ≥12 years with severe hemophilia A.
Want to read more?
Please login or register first to view this content.
Next post in Bleeding Disorders
